查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594053

脑膜炎双球菌疫苗市场：按类型、类别、剂量类型、目标群体、最终用户划分 - 2025-2030 年全球预测

Meningococcal Vaccines Market by Type (Combination Vaccines, Conjugate Vaccines, Men B Vaccines), Category (Intramuscular, Subcutaneous), Dosage Type, Target Group, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年脑膜炎双球菌疫苗市场规模为54.5亿美元，预计2024年将达59.5亿美元，复合年增长率为10.50%，预计2030年将达到109.7亿美元。

脑膜炎双球菌疫苗市场范围是生产和部署预防脑膜炎双球菌感染疾病的疫苗，主要针对青少年和特定高风险族群。这项需求源自于脑膜炎双球菌病菌感染造成的严重健康威胁，这种感染会造成脑膜炎和败血症等毁灭性后果。这些疫苗主要用于公共卫生免疫策略，特别建议用于流行地区和具有特定健康风险的人。最终用途包括医疗保健提供者、诊所、政府卫生机构、研究机构等。主要成长动力包括政府对免疫计划的兴趣增加、疾病风险意识的提高以及疫苗配方的技术进步。值得注意的是，COVID-19 大流行强化了疫苗接种的重要性，并间接提高了投资和意识，为市场相关人员提供了扩大支持和教育力度的机会。目前的商机包括为疾病负担高的新兴国家开发更便宜、更容易取得的疫苗，以及疫苗储存和供应技术的创新。然而，低收入地区对疫苗接种犹豫不决、监管障碍和后勤障碍等挑战阻碍了市场扩张。此外，在更广泛的感染疾病领域，来自其他生物製药和预防性治疗的竞争带来了市场饱和的风险。创新的要点是提高疫苗功效、提高血清群覆盖率以及改进递送机制（例如无针选择）。个人化医疗和基于 mRNA 的疫苗也呈现成长趋势，市场可以探索。市场前景广阔但复杂，我们正在寻求利用全球免疫领域的新机会，平衡战略支持工作，例如投资研究和与公共卫生机构合作，我们需要利用它并克服其固有的问题。

主要市场统计
基准年[2023] 54.5亿美元
预测年份 [2024] 59.5亿美元
预测年份 [2030] 109.7亿美元
复合年增长率（%） 10.50%

市场动态：快速发展的脑膜炎双球菌疫苗市场的关键市场洞察

供需的动态交互作用正在改变脑膜炎球菌疫苗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球脑膜炎发生率不断上升
    • 活性化研发活动和正在进行中的疫苗开发
    • 加强免疫计画和政府针对脑膜炎双球菌疾病的努力
  • 市场限制因素
    • 生产成本高
  • 市场机会
    • 改善新兴国家细菌性脑膜炎的发生率和监测系统
    • 加强合作研究和伙伴关係以支持疫苗开发
  • 市场挑战
    • 脑膜炎双球菌疫苗的限制和副作用

波特的五力：驾驭脑膜炎双球菌疫苗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解脑膜炎双球菌疫苗市场的外部影响

外部宏观环境因素在塑造脑膜炎双球菌疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解脑膜炎双球菌疫苗市场的竞争格局

对脑膜炎双球菌疫苗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵脑膜炎双球菌疫苗市场供应商的绩效评估

FPNV定位矩阵是评估脑膜炎双球菌疫苗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了脑膜炎双球菌疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对脑膜炎双球菌疫苗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球脑膜炎发生率增加
      • 增加研发活动和正在进行的疫苗开发
      • 加强免疫计画和政府针对病菌感染疾病的努力
    • 抑制因素
      • 脑膜炎双球菌疫苗生产成本高
    • 机会
      • 改善新兴国家细菌性脑膜炎的发生率和监测系统
      • 加强合作和伙伴关係以支持疫苗开发
    • 任务
      • 脑膜炎双球菌疫苗的限制和副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章脑膜炎双球菌疫苗市场：依类型

  • 联合疫苗
    • 混合体
    • 梅尼特里克斯
  • 结合疫苗
    • 梅纳克特拉
    • 梅纳夫里瓦克
    • 脑膜炎科技
    • 门朱盖特
    • 门贝奥
    • 尼斯巴克C
    • 尼门里克斯
    • NmVac4-DT
  • 男性 B 疫苗
    • 贝克塞洛
    • 托门巴
  • 多醣体疫苗
    • 门塞瓦克斯
    • 梅农宗
    • ＮｍＶａｃ４

第七章脑膜炎双球菌疫苗市场：依类别

  • 肌肉注射
  • 皮下的

第八章按剂量类型分類的脑膜炎双球菌疫苗市场

  • 额外疫苗接种
  • 初级疫苗接种

第九章目标族群脑膜炎双球菌疫苗市场

  • 成人用
  • 青春期前的
  • 青少年

第 10 章 脑膜炎双球菌疫苗市场：依最终使用者分类

  • 医院药房
  • 小儿科诊所
  • 零售药房

第十一章美洲脑膜炎球菌疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区脑膜炎双球菌疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲脑膜炎双球菌疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Bio-Manguinhos
  • Bio-Med（P）Limited
  • CanSino Biologics Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • Incepta Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Nanolek, LLC
  • Novartis AG
  • Panacea Biotec Ltd.
  • Petrovax Pharm
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Fosun Pharmaceutical（Group）Co., Ltd.
  • Sinovac Biotech Ltd.
  • SK bioscience
  • Taj Pharmaceuticals Limited
  • Vabiotech
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-430D42AA101A

The Meningococcal Vaccines Market was valued at USD 5.45 billion in 2023, expected to reach USD 5.95 billion in 2024, and is projected to grow at a CAGR of 10.50%, to USD 10.97 billion by 2030.

The scope of the meningococcal vaccines market entails production and deployment of vaccines designed to prevent infections caused by Neisseria meningitidis, targeting primarily adolescents and young adults as well as certain high-risk groups. The necessity arises from the serious health threat posed by meningococcal disease, which can result in devastating outcomes such as meningitis and septicemia. These vaccines are employed primarily in public health immunization strategies and are specifically recommended in outbreak-prone regions and for individuals with specific health risks. The end-use scope encompasses healthcare providers, clinics, governmental health organizations, and research institutions. Key growth drivers include heightened government focus on immunization programs, rising awareness about the disease's risks, and technological advancements in vaccine formulations. Notably, the COVID-19 pandemic reinforced the importance of vaccination, indirectly boosting investments and awareness, presenting opportunities for market players to expand outreach and educational efforts. Current opportunities include developing more affordable and accessible vaccine options for developing countries, where disease burden is often higher, as well as innovations in vaccine storage and delivery technologies. However, challenges such as vaccine hesitancy, regulatory hurdles, and logistical barriers in low-income regions stifle market expansion. Additionally, the competition from other biologic and preventive treatments in broader infectious disease domains presents market saturation risks. Innovations largely lie in enhancing vaccine efficacy, broadening serogroup coverage, and improving delivery mechanisms, such as needle-free options. There is a rising trend towards personalized medicine and mRNA-based vaccines, which the market can explore. The meningococcal vaccines market showcases a promising yet complex dynamic that requires balancing strategic outreach with investment in research and collaboration with public health entities to overcome inherent limitations while capitalizing on emerging opportunities in the global immunization landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 5.45 billion
Estimated Year [2024] USD 5.95 billion
Forecast Year [2030] USD 10.97 billion
CAGR (%) 10.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Meningococcal Vaccines Market

The Meningococcal Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Incidence of Meningitis Across the World
    • Rising R&D Activities and Vaccines Developments in the Pipeline
    • Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
  • Market Restraints
    • High Cost of Meningococcal Vaccines Production
  • Market Opportunities
    • Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
    • Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
  • Market Challenges
    • Limitations and Side Effects Associated with Meningococcal Vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Meningococcal Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Meningococcal Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Meningococcal Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Meningococcal Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Meningococcal Vaccines Market

A detailed market share analysis in the Meningococcal Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Meningococcal Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Meningococcal Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Meningococcal Vaccines Market

A strategic analysis of the Meningococcal Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Meningococcal Vaccines Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Bio-Manguinhos, Bio-Med (P) Limited, CanSino Biologics Inc., Chongqing Zhifei Biological Products Co., Ltd., Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Pharmaceuticals Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Nanolek, LLC, Novartis AG, Panacea Biotec Ltd., Petrovax Pharm, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Sinovac Biotech Ltd., SK bioscience, Taj Pharmaceuticals Limited, Vabiotech, and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Meningococcal Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Combination Vaccines, Conjugate Vaccines, Men B Vaccines, and Polysaccharide Vaccines. The Combination Vaccines is further studied across MenHibrix and Menitorix. The Conjugate Vaccines is further studied across Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, and NmVac4-DT. The Men B Vaccines is further studied across Bexsero and Trumenba. The Polysaccharide Vaccines is further studied across Mencevax, Menomune, and NmVac4.
  • Based on Category, market is studied across Intramuscular and Subcutaneous.
  • Based on Dosage Type, market is studied across Booster Vaccination and Primary Vaccination.
  • Based on Target Group, market is studied across Adult, Preteen, and Teenager.
  • Based on End-User, market is studied across Hospital Pharmacies, Pediatric Clinic, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence of Meningitis Across the World
      • 5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
      • 5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost of Meningococcal Vaccines Production
    • 5.1.3. Opportunities
      • 5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
      • 5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Meningococcal Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Combination Vaccines
    • 6.2.1. MenHibrix
    • 6.2.2. Menitorix
  • 6.3. Conjugate Vaccines
    • 6.3.1. Menactra
    • 6.3.2. MenAfriVac
    • 6.3.3. Meningitec
    • 6.3.4. Menjugate
    • 6.3.5. Menveo
    • 6.3.6. NeisVac-C
    • 6.3.7. Nimenrix
    • 6.3.8. NmVac4-DT
  • 6.4. Men B Vaccines
    • 6.4.1. Bexsero
    • 6.4.2. Trumenba
  • 6.5. Polysaccharide Vaccines
    • 6.5.1. Mencevax
    • 6.5.2. Menomune
    • 6.5.3. NmVac4

7. Meningococcal Vaccines Market, by Category

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Subcutaneous

8. Meningococcal Vaccines Market, by Dosage Type

  • 8.1. Introduction
  • 8.2. Booster Vaccination
  • 8.3. Primary Vaccination

9. Meningococcal Vaccines Market, by Target Group

  • 9.1. Introduction
  • 9.2. Adult
  • 9.3. Preteen
  • 9.4. Teenager

10. Meningococcal Vaccines Market, by End-User

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Pediatric Clinic
  • 10.4. Retail Pharmacies

11. Americas Meningococcal Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Meningococcal Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Meningococcal Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Astellas Pharma Inc.
  • 2. AstraZeneca PLC
  • 3. Bavarian Nordic A/S
  • 4. Bharat Biotech Ltd.
  • 5. Bio-Manguinhos
  • 6. Bio-Med (P) Limited
  • 7. CanSino Biologics Inc.
  • 8. Chongqing Zhifei Biological Products Co., Ltd.
  • 9. Emergent BioSolutions Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Incepta Pharmaceuticals Ltd.
  • 12. Merck & Co., Inc.
  • 13. Mitsubishi Tanabe Pharma Corporation
  • 14. Nanolek, LLC
  • 15. Novartis AG
  • 16. Panacea Biotec Ltd.
  • 17. Petrovax Pharm
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. Serum Institute of India Pvt. Ltd.
  • 21. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • 22. Sinovac Biotech Ltd.
  • 23. SK bioscience
  • 24. Taj Pharmaceuticals Limited
  • 25. Vabiotech
  • 26. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. MENINGOCOCCAL VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MENINGOCOCCAL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENHIBRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENITORIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENAFRIVAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENINGITEC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENJUGATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NEISVAC-C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NIMENRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4-DT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BEXSERO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TRUMENBA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENCEVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY MENOMUNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY BOOSTER VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRIMARY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PRETEEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY TEENAGER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR MENINGOC